25 patents
Utility
Injectable Formulations of Ibudilast
18 Jan 24
A injectable pharmaceutical compositions consists of a buffered aqueous solution comprising (a) about 5% w/v to about 15% w/v sulfobutylether-β-cyclodextrin (SBE-β-CD), and about 0.05% w/v to about 0.5% w/v ibudilast, or (b) about 5% w/v to about 25% w/v polyoxyl castor oil, and about 1% w/v to about 5% w/v ibudilast.
Kazuko MATSUDA, Federico Carlos Aréjola Gaeta, Yuichi IWAKI
Filed: 12 Jul 23
Utility
Ibudilast oral formulations and methods of using same
9 Jan 24
This disclosure is directed to ibudilast higher dosage oral formulations, such as tablet or capsule formulations, and the corresponding methods of treatment.
Kazuko Matsuda, Federico Carlos Aréjola Gaeta
Filed: 21 Sep 20
Utility
Methods of Treating Post-covid Condition(s)
14 Sep 23
Disclosed is a method of treating post-COVID condition(s) in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
Kazuko Matsuda
Filed: 31 Jan 23
Utility
Methods of Minimizing Cancer Metastasis
13 Apr 23
A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
Kazuko Matsuda, Federico Carlos Aréjola Gaeta
Filed: 25 Jul 22
Utility
Methods of Treating Glioblastoma Multiforme Using Combination Therapy
23 Mar 23
Disclosed herein are compositions and methods for treating glioblastoma in a patient in need thereof by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor.
Kazuko Matsuda, Michael Vogelbaum, Justin Lathia
Filed: 19 Sep 22
Utility
Methods of Preventing Cancer Metastasis
2 Feb 23
A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
Kazuko Matsuda, Grazia Ambrosini, Gary K. Schwartz, Alex J. Rai
Filed: 25 Jul 22
Utility
Methods to Decrease Triglyceride Synthesis In the Liver
8 Dec 22
Kazuko Matsuda, Masatsune Ogura
Filed: 26 May 22
Utility
Methods and dosing regimens using ibudilast and a second agent for cancer therapy
20 Sep 22
Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.
Kazuko Matsuda, Kerrie McDonald
Filed: 10 Jul 20
Utility
Methods of Treating Chemical Gas Exposure
4 Aug 22
A method of treating chemical-induced lung injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
Kazuko Matsuda, Federico Carlos Aréjola Gaeta
Filed: 27 Jan 22
Utility
Treatment of Progressive Neurodegenerative Disease with Ibudilast
2 Jun 22
Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
Michael E. Kalafer, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
Filed: 2 Jul 21
Utility
Combination of ibudilast and riluzole and methods of using same
22 Mar 22
The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms.
Kazuko Matsuda, Yuichi Iwaki
Filed: 18 Jun 20
Utility
Methods of treating ophthalmic disease/disorder or injury with ibudilast
26 Oct 21
This disclosure is directed to methods of treating ophthalmic disease/disorder or injury associated with neurodegenerative disease/disorder, such as progressive multiple sclerosis, or a neuro-ophthalmologic disorder in human patients using ibudilast.
Kazuko Matsuda
Filed: 18 Oct 19
Utility
Methods of Reducing Plasma Level of Macrophage Migratory Inhibitory Factor In Patients
7 Oct 21
Disclosed is a method of reducing plasma level of macrophage migratory inhibitory factor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
Yuichi IWAKI, Kazuko MATSUDA
Filed: 5 Apr 21
Utility
Treatment of progressive neurodegenerative disease with ibudilast
10 Aug 21
Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
Filed: 1 May 19
Utility
Methods of Suppressing Myeloid-derived Suppressor Cells In Patients
17 Jun 21
Methods of suppressing myeloid-derived suppressor cells (MDSCs), reducing immune suppression, reducing regulatory T-cell count and increasing CD4+ T-cell count in cancer patients using ibudilast.
Kazuko Matsuda
Filed: 31 Jul 20
Utility
Ibudilast Oral Formulations and Methods of Using Same
25 Mar 21
This disclosure is directed to ibudilast higher dosage oral formulations, such as tablet or capsule formulations, and the corresponding methods of treatment.
Kazuko Matsuda, Federico Carlos Aréjola Gaeta
Filed: 21 Sep 20
Utility
Combination of ibudilast and interferon-beta and methods of using same
16 Mar 21
This disclosure is directed to methods of alleviating the negative effects of, treating, or slowing the progression of progressive multiple sclerosis in human patients using ibudilast and interferon-beta.
Kazuko Matsuda
Filed: 8 Oct 19
Utility
Methods and Dosing Regimens Using Ibudilast and a Second Agent for Cancer Therapy
28 Jan 21
Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.
Kazuko Matsuda, Kerrie McDonald
Filed: 10 Jul 20
Utility
Combination of Ibudilast and Riluzole and Methods of Using Same
6 Jan 21
The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms.
Kazuko Matsuda, Yuichi Iwaki
Filed: 17 Jun 20
Utility
Methods and dosing regimens using ibudilast and a second agent for cancer therapy
17 Aug 20
Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.
Kazuko Matsuda, Kerrie McDonald
Filed: 10 Feb 19